Thibault Constance, Gross-Goupil Marine
Service d'oncologie médicale, Hôpital européen Georges-Pompidou, CHU de Paris, 20, rue Leblanc, 75015 Paris, France.
Service d'oncologie médicale, Hôpital Saint-André, CHU de Bordeaux, 1, rue Jean-Burguet, 33075 Bordeaux, France.
Bull Cancer. 2020 Jun;107(5S):S6-S16. doi: 10.1016/S0007-4551(20)30273-3.
Until 2014, no new therapeutic agent have been approved by authorities in more than 2 decades for bladder cancer. But the panel of treatments has expended in recent years with the emergence of at least 3 different therapeutic classes. First, the immune checkpoint inhibitors that have demonstrated an overall survival benefit in metastatic patients after failure of platinum based chemotherapy. They are therefore currently evaluated alone or in combination with chemotherapy in multiple studies at earlier stages (localized and meta-static). The second and third therapeutic classes are the targeted therapies (especially FGFR inhibitor) and the antibody-drug conjugates with promising results in early clinical trials. In this article, we review all the current and future studies conducted in urothelial carcinoma of the bladder.
直到2014年，二十多年来监管部门未批准用于膀胱癌的新治疗药物。但近年来，随着至少3种不同治疗类别药物的出现，治疗方案有所增加。首先是免疫检查点抑制剂，已证实在铂类化疗失败的转移性患者中可带来总生存获益。因此目前正在多项早期（局部和转移性）研究中单独或与化疗联合进行评估。第二和第三类治疗药物是靶向治疗（尤其是FGFR抑制剂）以及在早期临床试验中取得了有前景结果的抗体药物偶联物。在本文中，我们综述了目前及未来针对膀胱尿路上皮癌开展的所有研究。
